Literature DB >> 90712

Absence of four H-2d antigenic specificites in an H-2d sarcoma.

F Garrido, M Perez, M D Torres.   

Abstract

MCG4 is a BALB/c sarcoma induced as a solid tumour with 0.2 mgs of methylcholantrene. The primary tumour was serially transplanted subcutaneously in syngeneic mice. The ascites form obtained was sued to study the expression of H-2 antigeneic specificities in a postlabelling radioassay. MCG4 did not express H-2D.4 (private specificity of H-2d haplotypes) as well as H-2.3, H-2.8 and H-2.13 (public specificities). In addition it expressed H-2.5 (a public specificity not present in H-2d cells). These results were confirmed by quantitative absorption analysis using MCG4 and positive-negative normal lymphoid cells for a particular specificity. Results are discussed with regard to the control of expression of H-2 antigens by regulatory genes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 90712     DOI: 10.1111/j.1744-313x.1979.tb00333.x

Source DB:  PubMed          Journal:  J Immunogenet        ISSN: 0305-1811


  4 in total

1.  Syngeneic tumor cells can induce alloreactive T killer cells: a biological role for transplantation antigens.

Authors:  V Schirrmacher; D Hübsch; F Garrido
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

2.  Unexpected H-2 antigen expression by mouse tumor cells, a cautionary note.

Authors:  P J Robinson; K Sege; P Altevogt; P A Peterson; L Lundin; F Garrido; V Schirrmacher
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

Review 3.  MHC heterogeneity and response of metastases to immunotherapy.

Authors:  Ignacio Algarra; Federico Garrido; Angel M Garcia-Lora
Journal:  Cancer Metastasis Rev       Date:  2021-04-15       Impact factor: 9.264

4.  HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas.

Authors:  M A López-Nevot; F Esteban; A Ferrón; J Gutiérrez; M R Oliva; C Romero; C Huelin; F Ruiz-Cabello; F Garrido
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.